Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Winder

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The Pharmacogenomics Journal|April 12, 2012
An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrenceT Winder, P M Wilson, D Yang, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 18, 2008
Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancerM Knauer, A Haid, Y Schneider, et al.
The Pharmacogenomics Journal|July 27, 2011
TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trialsP P Grimminger, M Shi, C Barrett, et al.
American Journal of Botany|June 10, 2011
The tortoise and the hare II: relative utility of 21 noncoding chloroplast DNA sequences for phylogenetic analysisJoey Shaw, Edgar B Lickey, John T Beck, et al.
ESMO Open|October 3, 2025
NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world dataA Reichinger, A Friedrich, T Lentner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patientsT Winder, P Bohanes, W Zhang, et al.
The Pharmacogenomics Journal|January 11, 2012
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapyA Pohl, A El-Khoueiry, D Yang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapyW Zhang, T Winder, Y Ning, et al.
JMIR Research Protocols|September 5, 2024
Digitizing Survivorship Care Plans Through the POST-Treatment Health Outcomes of Cancer Survivors (POSTHOC) Mobile App: Protocol for a Phase II Randomized Controlled TrialKaitlin H Chung, Shari M Youngblood, Carin L Clingan, et al.
Journal of Cancer Survivorship : Research and Practice|November 27, 2025
Leveraging technology to address POST-Treatment Health Outcomes of Cancer Survivors (POSTHOC): A phase I/II randomized controlled trial of a survivorship care plan mobile applicationShalet James, Carin L Clingan, Ikmat A Adesanya, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Pharmacogenomics Journal|April 12, 2012
An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrenceT Winder, P M Wilson, D Yang, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 18, 2008
Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancerM Knauer, A Haid, Y Schneider, et al.
The Pharmacogenomics Journal|July 27, 2011
TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trialsP P Grimminger, M Shi, C Barrett, et al.
American Journal of Botany|June 10, 2011
The tortoise and the hare II: relative utility of 21 noncoding chloroplast DNA sequences for phylogenetic analysisJoey Shaw, Edgar B Lickey, John T Beck, et al.
ESMO Open|October 3, 2025
NALIRIFOX in the treatment of metastatic pancreatic ductal adenocarcinoma: an exploratory analysis of real-world dataA Reichinger, A Friedrich, T Lentner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 9, 2011
GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patientsT Winder, P Bohanes, W Zhang, et al.
The Pharmacogenomics Journal|January 11, 2012
Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapyA Pohl, A El-Khoueiry, D Yang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2010
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapyW Zhang, T Winder, Y Ning, et al.
JMIR Research Protocols|September 5, 2024
Digitizing Survivorship Care Plans Through the POST-Treatment Health Outcomes of Cancer Survivors (POSTHOC) Mobile App: Protocol for a Phase II Randomized Controlled TrialKaitlin H Chung, Shari M Youngblood, Carin L Clingan, et al.
Journal of Cancer Survivorship : Research and Practice|November 27, 2025
Leveraging technology to address POST-Treatment Health Outcomes of Cancer Survivors (POSTHOC): A phase I/II randomized controlled trial of a survivorship care plan mobile applicationShalet James, Carin L Clingan, Ikmat A Adesanya, et al.
Pageof 4